Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-826476
Alvespimycin · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Patients whose last dose is \> 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin Patients whose last dose is \< 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin |
| Arm 2 | EXPERIMENTAL | Patients whose last dose is \> 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin Patients whose last dose is \< 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin |
| Name | Type | Description |
|---|---|---|
| Alvespimycin | DRUG | Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT |
| Trastuzumab | DRUG | Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT |
| Paclitaxel | DRUG | Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT |
Inclusion Criteria: * KPS performance status \>= 70% * Schedule A: all patients must have a histologically confirmed solid tumor malignancy. Schedule B: patients must have metastatic breast cancer with Her2 amplification by FISH or 3+ Her2 overexpression by immunohistochemistry ("IHC"). Patients ar...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Alvespimycin is an investigational small molecule developed by Bristol-Myers Squibb Company (ticker BMY) for the treatment of solid tumors. It is an HSP90 inhibitor that has been studied in Phase 1 clinical development, including in patients with advanced solid tumor malignancies and HER2 positive metastatic breast cancer.
Alvespimycin targets HSP90AA1 and HSP90AB1, two isoforms of the heat shock protein 90 chaperone. It acts as an inhibitor of these targets. By binding HSP90, the drug interferes with the chaperone function that supports the folding and stability of client proteins involved in tumor growth.
Alvespimycin is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company sponsored the Phase 1 clinical trial of the agent in advanced solid tumors and HER2 positive metastatic breast cancer.
Alvespimycin is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The single registered trial, NCT00803556, has been completed, and no active trials of alvespimycin are currently listed.
Alvespimycin has been evaluated in one completed Phase 1 trial, NCT00803556. That study tested intravenous alvespimycin (KOS-1022) combined with trastuzumab, with or without paclitaxel, in patients with advanced solid tumor malignancies or HER2 positive metastatic breast cancer who had previously failed trastuzumab therapy. It enrolled 29 patients in the United States.
Yes, alvespimycin is also known as KOS-1022. The two names refer to the same investigational HSP90 inhibitor developed by Bristol-Myers Squibb. The Phase 1 trial NCT00803556 used the KOS-1022 designation in its title when studying the intravenous formulation in advanced solid tumors and HER2 positive metastatic breast cancer.